Ribonuclease T1 (RNase T1)

An enzyme catalyzing the endonucleolytic cleavage of RNA at the 3'-position of a guanylate residue. EC 3.1.27.3.

Also Known As:

RNase T1; Aspergillus oryzae Ribonuclease; Guanyl-Specific RNase; RNase Apl; RNase F1; RNase Pch 1; RNase ST; Ribonuclease F1; Ribonuclease F2; Ribonuclease ST; Ribonuclease T-1; T 1 RNase; Guanyl Specific RNase; RNase, Guanyl-Specific; RNase, T 1; Ribonuclease T 1; Ribonuclease, Aspergillus oryzae; Guanyloribonuclease; Ribonuclease N1; Ribonucleate 3'-guanylo-oligonucleotidohydrolase

Networked: 30 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Esterases: 1574
      - Ribonucleases: 2046
        Endoribonucleases: 176
        Ribonuclease T1: 30
        ribonuclease Po1
      - Endonucleases: 1227
        Endoribonucleases: 176
        Ribonuclease T1: 30
        ribonuclease Po1

Experts

1.	Gavilanes, José G: 2 articles (10/2019 - 09/2012)
2.	Lacadena, Javier: 2 articles (10/2019 - 09/2012)
3.	Tomé-Amat, Jaime: 2 articles (10/2019 - 09/2012)
4.	Inokuchi, Norio: 2 articles (01/2014 - 01/2013)
5.	Itagaki, Tadashi: 2 articles (01/2014 - 01/2013)
6.	Kobayashi, Hiroko: 2 articles (01/2014 - 01/2013)
7.	Motoyoshi, Naomi: 2 articles (01/2014 - 01/2013)
8.	Lázaro-Gorines, Rodrigo: 1 article (10/2019)
9.	Ruiz-de-la-Herrán, Javier: 1 article (10/2019)
10.	Akita, Fusamichi: 1 article (01/2014)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2004 - "However, we believe that RNase T1 incorporated in HVJ envelope vector will be a unique anticancer drug if HVJ envelope vector can be targeted to tumor cells." 09/01/2004 - "In this study, we internalized RNase T1 into human tumor cells via a novel gene transfer reagent, hemagglutinating virus of Japan (HVJ) envelope vector, which resulted in cell death. " 01/01/2014 - "We previously reported that RNase Po1 inhibits the proliferation of human tumor cells, yet RNase T1 and other T1 family RNases are non-toxic. " 01/01/2013 - "The inhibition of human tumor cell proliferation by RNase Pol, a member of the RNase T1 family, from Pleurotus ostreatus." 09/01/2004 - "On the other hand, although its structure is related to that of alpha-sarcin, RNase T1 is noncytotoxic because of its inability to internalize into tumor cells. "
2.	Genomic Instability 01/01/1989 - "We have used ribonuclease T1 oligonucleotide fingerprint analysis to study genomic stability of La Crosse virus (Bunyaviridae) during vertical and horizontal transmission in the laboratory. "
3.	Glioma (Gliomas) 02/01/1996 - "These putative cis/trans interactions were examined in the present studies with RNase T1 protection assays using 32P-labeled GLUT1 3'-UTR prepared from transcription plasmids and cytosolic proteins from C6 rat glioma cells. "
4.	Vesicular Stomatitis 10/01/1982 - "We examined the kinetics of synthesis in vitro of the 5' ends of the vesicular stomatitis virus mRNAs by analysis of specific RNase T1 oligonucleotides located near the 5' ends of the mRNAs. " 01/01/1981 - "RNA genomes from standard vesicular stomatitis virus and two defective interfering (DI) particles dI 0.33 (DI-T) and DI 0.52, were purified and digested with RNase T1. " 02/01/1980 - "RNase T(1) oligonucleotide fingerprint analyses of three vesicular stomatitis virus Indiana serotype small defective interfering (DI) particle RNA species indicate that they only have oligonucleotides derived from the 5' region of the viral genome. " 04/01/1979 - "Analyses of prototype vesicular stomatitis (VSV, Indiana serotype) mRNA-32P-labeled viral RNA duplexes have established the assignments of 65 of the 72 large oligonucleotides that are recovered by two-dimensional electrophoresis of RNase T1 digests of the viral RNA. " 11/01/1973 - "Using both pancreatic RNase and RNase T(1) to digest viral RNA labeled by (3)H-uridine, (3)H-cytidine, or (3)H-guanosine, the weight of the virion RNA of vesicular stomatitis virus (VSV) is estimated as 3.82 +/- 0.14 x 10(6) whereas that of the VSV-defective T particle is estimated as 1.23 +/- 0.04 x 10(6)."
5.	Infections 10/01/1994 - "Comparisons of RNase T1 two-dimensional maps and nucleotide sequences of the VP1-coding region revealed a continual, although irregular, increase in the fixation of mutations as the infection progressed. " 06/25/1985 - "RNase T1 finger prints of this species, isolated before or after wt infection, were compared with that of an in vitro ligated pair of CTr5x-specific fragments. " 02/25/2007 - "Viral isolates collected from esophageal-pharyngeal (EP) fluids for up to 71 weeks after infection were analyzed at different times by nucleotide sequencing and T(1) RNase oligonucleotide fingerprinting to assess variability in the VP1-coding region and in the complete genome, respectively. " 01/01/1988 - "Analysis of the viral RNAs of the positive samples by means of RNase T1 maps on one- and two-dimensional gels showed (1) changes in the electrophoretic mobility of the poly(C)-rich tracts of viruses recovered from the OP fluids at various times after infection; (2) selection of virus populations with poly(C)-rich tracts of increased size; (3) later on, changes in the patterns of oligonucleotides of persistent viruses. "

Related Drugs and Biologics

1.	Oligonucleotides
2.	Proteins (Proteins, Gene)
3.	Indicators and Reagents (Reagents)
4.	RNA (Ribonucleic Acid)
5.	Ribonucleases (Ribonuclease)
6.	Viral RNA
7.	Pancreatic Ribonuclease (Ribonuclease A)
8.	Single-Chain Antibodies
9.	Glucose Transporter Type 1
10.	Furin